Uptravi and Gastrooesophageal reflux disease for Women aged 60+ (a phase IV clinical study of FDA data)

Summary:

Gastrooesophageal reflux disease is found for women aged 60+ who take Uptravi (selexipag). This study is created by eHealthMe based on reports of 8,352 women aged 60+ from the FDA, and is updated regularly. The information that eHealthMe analyzes includes:

Time on Uptravi when people have Gastrooesophageal reflux disease
Top conditions
Top co-used drugs
Top other side effects

On Jan, 30, 2026

8,352 women aged 60+ reported to have side effects when taking Uptravi.
Among them, 175 people (2.1%) have Gastrooesophageal reflux disease

What is Uptravi?

Uptravi has active ingredients of selexipag. eHealthMe is studying from 26,576 Uptravi users. Check the latest studies of Uptravi.

What is Gastrooesophageal reflux disease?

Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus) is found to be associated with 3,176 drugs and 3,596 conditions by eHealthMe. Check the latest studies of Gastrooesophageal reflux disease.

Number of reports submitted per year:

Could Uptravi cause Gastrooesophageal reflux disease in women aged 60+?

Time on Uptravi when people have Gastrooesophageal reflux disease *

Severity of Gastrooesophageal reflux disease

n/a

How people recovered from Gastrooesophageal reflux disease

n/a

Top conditions involved for these people *:

You may use this to check any potential undetected conditions.

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 132 people, 75.43%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 27 people, 15.43%
Constipation: 13 people, 7.43%
Pain: 9 people, 5.14%
Nausea (feeling of having an urge to vomit): 9 people, 5.14%
Gastritis - Chronic (long lasting inflammation of stomach): 8 people, 4.57%
Necrosis (the death of body tissue): 8 people, 4.57%
Peripheral Vascular Disorder: 6 people, 3.43%
Cardiac Failure: 5 people, 2.86%
Insomnia (sleeplessness): 5 people, 2.86%

Top co-used drugs for these people *:

You may use this to check any potential interacting drugs.

Top other side effects for these people *:

You may use this to check any potential undetected side effects.

Headache (pain in head): 105 people, 60.00%
Dyspnea (difficult or laboured breathing): 92 people, 52.57%
Diarrhea: 88 people, 50.29%
Nausea (feeling of having an urge to vomit): 88 people, 50.29%
Dizziness: 66 people, 37.71%
Fatigue (feeling of tiredness): 66 people, 37.71%
Pain In Extremity: 62 people, 35.43%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 59 people, 33.71%
Muscle Aches (muscle pain): 56 people, 32.00%
Pain: 55 people, 31.43%

* Approximation only. Some reports may have incomplete information.

Do you take Uptravi and have Gastrooesophageal reflux disease?

- Check whether Gastrooesophageal reflux disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies:

Uptravi and Gastrooesophageal reflux disease

How the study uses the data?

The study is based on (applicable) gender, age, selexipag (the active ingredients of Uptravi) and Uptravi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.